Search tips
Search criteria 


Logo of bmjThe BMJ
BMJ. 1996 November 2; 313(7065): 1127–1130.
PMCID: PMC2352463

Factor V Leiden: should we screen oral contraceptive users and pregnant women?


The factor V Leiden mutation is the most common genetic risk factor for deep vein thrombosis: it is present in about 5% of the white population. The risk of deep vein thrombosis among women who use oral contraceptives is greatly increased by the presence of the mutation. The same seems to be true of the risk of postpartum thrombosis. Several authors have called for all women to be screened before prescription of oral contraceptives and during pregnancy. Such a policy might deny effective contraception to a substantial number of women while preventing only a small number of deaths due to pulmonary emboli. Moreover, in pregnancy the ensuing use of oral anticoagulation prophylaxis might carry a penalty of fatal bleeding that is equal to or exceeds the risk of death due to postpartum thrombosis. It might pay, however, to take a personal and family history of deep vein thrombosis when prescribing oral contraceptives or at a first antenatal visit to detect women from families with a tendency to multiple thrombosis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995 Dec 16;346(8990):1593–1596. [PubMed]
  • Pasi KJ, Perry DJ, Lee CA. Thromboembolism and the combined oral contraceptive pill. Lancet. 1995 Jun 3;345(8962):1437–1437. [PubMed]
  • Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995 Jul;173(1):210–213. [PubMed]
  • Dahlbäck B. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost. 1995 May;73(5):739–742. [PubMed]
  • Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest. 1994 Sep;94(3):923–927. [PMC free article] [PubMed]
  • Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995 Dec 16;346(8990):1589–1593. [PubMed]
  • Anderson FA, Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991 May;151(5):933–938. [PubMed]
  • Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. [PubMed]
  • Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995 Apr 6;332(14):912–917. [PubMed]
  • Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med. 1995 Jul;238(1):31–37. [PubMed]
  • Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost. 1996 Mar;75(3):524–525. [PubMed]
  • Carter CJ. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis. 1994 May-Jun;36(6):423–438. [PubMed]
  • Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995 Nov 15;92(10):2800–2802. [PubMed]
  • Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. Br Med J. 1974 Feb 9;1(5901):215–217. [PMC free article] [PubMed]
  • Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood. 1995 Mar 15;85(6):1504–1508. [PubMed]
  • Briët E, van der Meer FJ, Rosendaal FR, Houwing-Duistermaat JJ, van Houwelingen HC. The family history and inherited thrombophilia. Br J Haematol. 1994 Jun;87(2):348–352. [PubMed]
  • Majerus PW. Human genetics. Bad blood by mutation. Nature. 1994 May 5;369(6475):14–15. [PubMed]
  • Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet. 1983 Aug;21(4):327–331. [PubMed]
  • Sachs BP, Brown DA, Driscoll SG, Schulman E, Acker D, Ransil BJ, Jewett JF. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med. 1987 Mar 12;316(11):667–672. [PubMed]
  • van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993 Jul 12;153(13):1557–1562. [PubMed]
  • Fihn SD. Aiming for safe anticoagulation. N Engl J Med. 1995 Jul 6;333(1):54–55. [PubMed]
  • Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994 Jun 8;271(22):1780–1785. [PubMed]
  • Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med. 1996 Jul 11;335(2):108–114. [PubMed]
  • Dahlbäck B. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. J Intern Med. 1995 Mar;237(3):221–227. [PubMed]
  • Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmann E, Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost. 1994 Apr;71(4):441–445. [PubMed]

Articles from The BMJ are provided here courtesy of BMJ Publishing Group